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ABSTRACT

	
  
	
  
The discovery of the endocannabinoid system propelled understanding of the
mechanisms of action of cannabinoid compounds. While marijuana is the most widely
used illicit substance in the world, the neuropsychopharmacological mechanisms that
underlie the diffuse effects of cannabis in the brain remain poorly understood. This is
because marijuana smoke represents a complex mixture of chemical components,
possessing dissociable psychoactive properties. Clinical evidence suggests a functional
dissociation between the two main pharmacological components of cannabis, Δ9tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD). Using a combination of cortical
microinfusions during two emotional learning paradigms, and single-unit in vivo
electrophysiological recording, we investigated the effects of phytocannabinoid
compounds in emotional regulation neural circuits, specifically the nucleus accumbens
shell. We report the first demonstration of hedonic properties of CBD; an effect mediated
by 5-HT1A receptors, and decreased VTA dopaminergic activity. In olfactory fear
conditioning, Δ9-THC potentiates and CBD attenuates emotionally salient stimuli similar
to synthetic cannabinoids.
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Chapter 1. General Introduction
In order to coordinate normative cognition and appropriate behavioural responses, the
brain must accurately process the emotional and motivational significance of an
enormous amount of incoming sensory stimuli. This requires the formation of adaptive
learned associations between the emotional salience of sensory inputs with their
respective environmental cues (Laviolette & Grace, 2006).
Several cortical and subcortical structures comprise the emotional processing
circuitry known as the mesocorticolimbic system, including: the medial prefrontal cortex
(mPFC), the basolateral amygdala (BLA), the ventral tegmental area (VTA) and the
nucleus accumbens (NAcc). These areas contain high levels of dopamine (DA) and
cannabinoid CB1 receptors, which are critical in emotional and motivational salience
processing and associative learning (Herkenham et al., 1991b; Moldrich & Wenger,
2000). Furthermore, previous research shows that the cannabinoid and DAergic systems
functionally interact, such that cortical CB1 transmission modulates subcortical
mesolimbic DA activity (Bossong et al., 2008; Diana, Melis, & Gessa, 1998).
Activation of the brain’s endocannabinoid system is associated with severe
distortions in emotional and motivational perceptions and with learning and memory
impairments (D’Souza et al., 2005). However, delivery of cannabinoids to the brain, via
drugs such as cannabis, represents a complex mixture of chemical components,
possessing dissociable psychoactive properties (ElSohly & Slade, 2005; Radwan et al.,
2009). Indeed, recent evidence suggests a functional dissociation between the two main
pharmacological

components

of

cannabis,

cannabidiol

(CBD)

and

Δ9-

tetrahydrocannabinol (Δ9-THC). Furthermore, human brain imaging evidence suggests
that Δ9-THC and CBD may exert differential psychological effects in distinct
mesocorticolimbic substrates (Bhattacharyya & Sendt, 2012; Bhattacharyya et al., 2012;
Bhattacharyya, Fusar-Poli, et al., 2009a; Bhattacharyya, et al., 2009b). The pharmacology
of these compounds is also quite distinct. CBD has been shown to be a weak antagonist
of the CB1 receptor (Thomas et al., 2009) as well as an agonist of the serotonin 5-HT1A
receptor (Russo, Burnett, Hall, & Parker, 2005); in contrast, Δ9-THC acts as a partial
CB1 agonist (Petitet, Jeantaud, Reibaud, Imperato, & Dubroeucq, 1998). While the
pharmacological properties of Δ9-THC and CBD are relatively well characterized, the
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differential effects of these distinct compounds on emotional processing in the brain
remain poorly understood. Furthermore, there are very few studies investigating the
effects of distinct Δ9-THC and CBD compounds in specific anatomical structures of the
brain.
The work presented in this thesis attempts to address some of the gaps in the current
understanding of the very complex nature of the major phytocannabinoids (plant-derived)
in the brain and the effects they have on emotional information processing and memory
formation. Specifically, this work investigates the dissociable psychoactive effects of Δ9THC and CBD microinfusions into the shell subdivision of the NAcc during two
emotional memory formation paradigms: conditioned place preference (CPP) and
olfactory fear conditioning. Through a series of behavioural, pharmacological and
electrophysiological experiments, I have also examined the interactions of these
compounds with the serotonergic and dopamanergic neurotransmitter systems to reveal
novel insights into the underlying neurobiological basis of exogenous cannabinoid
signaling in the mammalian brain.

1.1 The endocannabinoid system
	
  
The endocannabinoid (eCB) system is a ubiquitous lipid-based neuromodulatory system
within the nervous system that has been highly conserved across mammalian species and
plays diverse roles in normative physiological and psychological functioning (Elphick &
Egertova, 2001). Two main cannabinoid (CB) receptor subtypes exist in the nervous
system: the CB1 receptor, which is highly expressed in the central nervous system (CNS),
and the CB2 receptor which is expressed primarily in peripheral immune cells (Pertwee
& Ross, 2002). Given the neuroscientific nature of this work, this thesis will focus on
CB1 receptors. CB1 receptors are primarily expressed on the presynaptic axon terminals
of glutamatergic principal neurons as well as GABAergic projection and interneurons
(Katona & Freund, 2012), and are inhibitory G-protein coupled receptors (GPCR).
Activation of these receptors by their endogenous ligands anandamide (AEA) and 2arachidonoylglycerol (2-AG), or by exogenous cannabinoids such as those found in
cannabis, initiates a number of intra- and extracellular signaling events that serve to
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inhibit the cell, including: decreasing cytosolic cyclic adenosine monophosphate (cAMP)
production by inhibiting adenylate cyclase activity, closure of Ca2+ channels, and opening
of K+ channels (Lupica, Riegel, & Hoffman, 2004; Piomelli, 2003). The CB1 receptor is
the most ubiquitously expressed GPCR in the brains of both humans (Glass, Dragunow,
& Faull, 1997) and rats (Herkenham et al., 1991b) and, due to their location on the
primary excitatory and inhibitory cells in the brain, they play a crucial role in the
modulation of a number of other neurotransmitter systems including the dopaminergic
(DA), serotonergic (5-HT), GABAergic and glutamatergic systems (López-Moreno,
González-Cuevas, Moreno, & Navarro, 2008). The interaction between the eCB and DA
systems is of particular importance in the consideration of emotional processing and will
be discussed below.
1.1.1 Role of CB1 receptors in emotional processing
	
  
The eCB system, as mediated by CB1 receptors, plays a central role in the processing of
emotionally salient stimuli and related behaviours (Laviolette, 2014). The CB1 receptor is
highly expressed in the striatum, a series of structures involved in emotional and
motivational information processing, of both rats (Moldrich & Wenger, 2000) and
humans (Burns et al., 2007). In humans, use of cannabis as well as synthetic cannabinoid
analogues, both of which act on CB1 receptors, have profound effects on emotional
processing. Users report a wide array of emotional experiences ranging from euphoria
and sedation to anxiety, paranoia and agitation. Even acute exposure can result in moodrelated disturbances and alter the significance of external sensory input (Green,
Kavanagh, & Young, 2003; Rosenbaum, Carreiro, & Babu, 2012; Wachtel, ElSohly,
Ross, Ambre, & de Wit, 2002). In animal studies, mice lacking the CB1 receptor show
impairments in extinction learning of an aversive conditioned fear memory (Cannich et
al., 2004; Marsicano et al., 2002), and display an abnormal emotional phenotype
characterized by heightened aggressive, depressive and anxiety responses, in some
behavioural stress paradigms (Martin, Ledent, Parmentier, Maldonado, & Valverde,
2002). Pharmacological manipulations of CB1 receptors in various regions of the
mesocorticolimbic system also result in profound alterations of the salience of incoming
sensory stimuli. In olfactory fear conditioning experiments, rats receive an electric
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footshock during presentation of one of two distinct odours. Rats receiving intra-mPFC
microinfusions of the CB1 receptor agonist WIN-55,212-2 (WIN-55) prior to
conditioning with a normally non-salient subthreshold footshock display heightened
levels of freezing in response to the shock-paired odour, a measure of conditioned fear.
This effect was completely abolished using the CB1 receptor antagonist AM-251
(Laviolette, 2006). CB1 receptor transmission within the BLA—mPFC pathway is also
critical for the acquisition of emotionally salient associative memories. CB1 receptor
antagonism, administered systemically and as targeted microinfusions, blocks both the
behavioural acquisition of conditioned fear memories and LTP along the BLA—mPFC
pathway, a correlate of exposure to emotionally salient events (Tan, Lauzon, Bishop,
Bechard, & Laviolette, 2010). Follow-up electrophysiology studies show a bidirectional
effect of CB1 receptor modulation in the BLA, with mPFC neurons showing increased
neuronal activity in response to intra-BLA CB1 activation, and a decrease in activity
following CB1 antagonism (Tan et al., 2011). The studies outlined above serve to
illustrate the central role of CB1 receptors in the emotional processing structures of the
mesocorticolimbic pathway, however cannabinoid transmission within the NAcc remains
poorly understood and represents a potentially productive avenue of future research.

1.1.2 eCB interactions with the dopamine system
	
  
DAergic signaling also plays a critical role in emotional regulation and coordinated
behaviour in response to emotionally salient stimuli (Laviolette, 2007). While DA
receptors are expressed throughout the CNS, they display high levels of expression in the
limbic regions of the brain, suggesting a central role of DA in emotional and motivational
processes (Wise, 2004). Of particular note are DA efferents originating in the VTA that
project to higher level cortical structures of emotional regulation including the NAcc,
BLA and PFC (Grace, Floresco, Goto, & Lodge, 2007; Ikemoto, 2007). There are
profound anatomical and functional interactions between the eCB and DAergic systems.
CB1 receptors are expressed in the substantia nigra and striatum, regions that are highly
innervated by DAergic projections and express high levels of the DA receptor (Moldrich
& Wenger, 2000). Medium spiny neurons (MSN), the primary output neurons of the
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striatum, also express both CB1 and DA receptors (Glass & Felder, 1997; Herkenham et
al., 1991b). Furthermore, substantial evidence suggests that the CB1 and DA receptors
are coexpressed on synaptic terminals (Chiu, Puente, Grandes, & Castillo, 2010), and
may even form CB1-DA heterodimer receptor complexes in some brain regions (Kearn,
2005). These data suggest that CB1 signaling may act as an important modulator of
DAergic transmission in emotional regulation circuits (Giuffrida et al., 1999).
Functionally, CB1 receptor modulation has been shown to play an important role
in DAergic transmission. Systemic administration of CB1 receptor agonists such as Δ9THC and WIN-55 increase DAergic neuronal activity in the VTA (Diana et al., 1998;
French, Dillon, & Wu, 1997), and also enhance the firing rate of PFC pyramidal neurons
to the VTA (Pistis, Porcu, Melis, Diana, & Gessa, 2001). Furthermore, a recent study
found that Δ9-THC and WIN-55 administration increase DA synthesis in key emotional
processing regions such as the dorsal striatum, NAcc, PFC and amygdala (Polissidis et
al., 2009), suggesting an active role of eCB transmission in the synthesis and activity of
subcortical DA signaling.

1.1.3 The eCB system in neuropsychiatric disorders
	
  
Given the importance of the eCB system in emotional information processing, it is not
surprising that dysfunctions in the eCB system have been implicated in a range of
neuropsychiatric disorders that are characterized by deficits in emotional regulation
(Parolaro, Realini, Viganò, Guidali, & Rubino, 2010). Much of the evidence supporting
this hypothesis comes from studies using CB1 receptor knockout (KO) animals. Mice
lacking the CB1 receptor show increased anxiety responses in response to chronic stress
(Martin et al., 2002), and display a depressive phenotype in the forced swim test (Steiner
et al., 2008) and tail suspension test (Aso et al., 2008), both behavioural models of
depression. CB1 KO animals also exhibit elevated serum levels of glucocorticoids
(Urigüen, Pérez-Rial, Ledent, Palomo, & Manzanares, 2004), suggesting dysfunction of
the hypothalamus-pituitary-adrenal (HPA) axis, a physiological correlate found in major
depressive disorder (Pariante & Lightman, 2008; Stokes, 1995), anxiety (Pariante, 2003)
and post-traumatic stress disorder (PTSD; Yehuda, 2002).
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Deficits in circulating eCB levels are also observed in these disorders, further
implicating eCB system dysfunction. Basal serum levels of AEA and 2-AG have been
found to be significantly lower in individuals diagnosed with major depressive disorder in
comparison to healthy controls (Hill, Miller, Carrier, Gorzalka, & Hillard, 2009). The
same group has shown the plasma levels of 2-AG are also significantly reduced in a
population of PTSD patients in comparison to normal controls (Hill et al., 2013).
Evidence from pharmacological studies also provides compelling evidence for the
role of the eCB system in various neuropsychiatric disorders. Both systemic injections
and targeted microinfusions of CB1 agonists into specific brain regions critically
involved in emotional processing have been found to be effective at reversing depressivelike behaviours in various animal models (Bambico, Katz, Debonnel, & Gobbi, 2007;
Hill & Gorzalka, 2005). Furthermore, pharmacological inhibition of fatty acid amide
hydrolase (FAAH), the enzyme responsible for degrading the endogenous AEA, shows
efficacy as an antidepressant and anxiolytic (Bortolato et al., 2007; Haller et al., 2009;
Scherma et al., 2008), further supporting the hypothesis that a reduction in eCB tone, in
addition to CB1 receptor deficits, may underlie depressive and anxiety-related symptoms.

1.1.4 Schizophrenia
	
  
There is also substantial evidence for severe dysfunction of the eCB system in individuals
suffering from schizophrenia. This dysfunction manifests both at the level of the CB1
receptor as well as a dysregulation of eCB tone. In addition, heavy cannabis use
constitutes a significant environmental risk factor for the development of schizophrenia
and related psychotic disorders (this will be discussed in more detail below, see section
1.2.1).
Neuroanatomical studies have revealed that the CB1 receptor is highly expressed
in brain regions implicated in the pathophysiology of schizophrenia including the PFC,
hippocampus, basal ganglia and anterior cingulate cortex (Glass et al., 1997). More recent
studies suggest that expression of the CB1 receptor in these areas may be altered in
schizophrenia. Binding of the cannabinoid radioligand [3H]CP55940 to the CB1 receptor
was shown to be higher in the dorsolateral-PFC of schizophrenic patients than in healthy
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controls (Dean, Sundram, Bradbury, Scarr, & Copolov, 2001). Dalton et al. (2011)
subsequently confirmed these findings and additionally provided evidence that CB1
receptor expression is significantly higher in paranoid schizophrenics as compared to
non-paranoid schizophrenics and healthy controls. Furthermore, both the anterior and
posterior cingulate cortex (ACC and PCC, respectively) display increased CB1 receptor
expression in individuals suffering from schizophrenia in comparison to normal controls
(Newell, Deng, & Huang, 2006; Zavitsanou, Garrick, & Huang, 2004). Studies
employing pharmacological manipulation of the eCB system also support a role for the
CB1 receptor in schizophrenia. Administration of the CB1 receptor agonist WIN-55
results in impairments in sensorimotor gating such as prepulse inhibition (PPI), an
information processing and attentional deficit that is evident in patients with
schizophrenia (Martin et al., 2003; Schneider & Koch, 2002). Furthermore,
administration of CB1 receptor agonists such as Δ9-THC, the main psychoactive
ingredient in cannabis, can produce a constellation of effects in humans that are
reminiscent of schizophrenic symptomatology (Bhattacharyya et al., 2012; Green et al.,
2003; Wachtel et al., 2002) and elicit hyperactivity of mesolimbic DA circuits (Diana et
al., 1998; French et al., 1997), a core pathophysiologcial feature of schizophrenia (see
section 1.2.1). These data suggest that dysfunction of the CB1 receptor may play a critical
role in the aberrant emotional processing observed in schizophrenia. Finally, there is
evidence to suggest that polymorphisms in the gene coding the CB1 receptor (CNR1)
may be correlated with an increased susceptibility to developing schizophrenia
(Chavarría-Siles et al., 2008), although the nature of this relationship is not fully
understood (Seifert, Ossege, Emrich, Schneider, & Stuhrmann, 2007).
Dysregulation of eCB tone is also evident in schizophrenia. In a population of
first-episode paranoid schizophrenic patients, researchers found a significant elevation in
cerebrospinal fluid levels of AEA as compared to healthy controls (Giuffrida et al., 2004;
Leweke, Giuffrida, Wurster, Emrich, & Piomelli, 1999), and clinical remission was
associated with a significant reduction in AEA levels (De Marchi et al., 2003). There is
also some evidence from animal studies, using a PCP model of schizophrenia, of
increased AEA levels in some brain regions (Seillier, Advani, Cassano, Hensler, &
Giuffrida, 2009; Viganò et al., 2008). Somewhat paradoxically, clinical studies have
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shown that AEA levels are inversely correlated with the severity of psychotic symptoms
suggesting that elevated eCB tone may be a compensatory adaptation in response to
abnormal neurotransmission in schizophrenia-related psychoses (Giuffrida et al., 2004;
Leweke et al., 2012).

1.2 Cannabis and phytocannabinoids
	
  
Although cannabis has been used for spiritual, medicinal and industrial purposes for
thousands of years, it wasn't until the isolation of Δ9-tetrahydrocannabinol (Δ9-THC), the
major psychoactive cannabinoid in cannabis, in 1964 that scientific understanding of
phytocannabinoids (plant-derived) truly began (Mechoulam & Gaoni, 1964). In 1990, a
group of researchers elucidated the structure and expression of an endogenous
cannabinoid receptor, which was dubbed the CB1 receptor (Matsuda, Lolait, Brownstein,
Young, & Bonner, 1990), indicating an endogenous target on which Δ9-THC acts in the
brain. This was quickly followed by the discovery of arachidonylethanolamide (AEA),
also known as “anandamide”, an endogenous ligand for the CB1 receptor (Devane et al.,
1992). Since these discoveries, research interest in the endocannabinoid system has
accelerated dramatically and the endocannabinoid system has been implicated in a wide
range of physiological and psychological functions (Elphick & Egertova, 2001).
However despite these advances, the neurobiological mechanisms through which
cannabis exerts its neuropsychological effects, especially at the level of discrete neural
circuits, remains poorly understood. This is in part because cannabis contains hundreds of
chemical compounds and over 70 known cannabinoids, each with distinct, dissociable
and complex pharmacological profiles (ElSohly & Slade, 2005; Radwan et al., 2009).
The two predominant cannabinoid compounds contained in cannabis are the psychoactive
Δ9-THC and the non-psychoactive cannabidiol (CBD; Russo & Guy, 2006), which will
be the focus of the work presented in this thesis. Recent basic and clinical evidence
suggests that these two compounds have very different pharmacological profiles and
dissociable neuropsychological properties (Bhattacharyya et al., 2009b). While Δ9-THC
administration generally produces subjective states of anxiety and agitation
(Bhattacharyya et al., 2012; Fusar-Poli et al., 2009), CBD has potent anxiolytic, and
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antipsychotic effects (Bhattacharyya et al., 2009a; Crippa et al., 2003; Crippa et al., 2010;
Schubart et al., 2013; Zuardi et al., 2012). Although the neurobiological basis for these
dissociable effects is not fully understood, it is likely a result of significant
pharmacological differences between Δ9-THC and CBD. While Δ9-THC is a partial
agonist of the CB1 receptor (Petitet et al., 1998), CBD is a weak CB1 receptor antagonist
(Thomas et al., 2009), and displays relatively high binding affinity for serotonin 5-HT1A
receptors (Russo et al., 2005). CBD also displays antagonistic properties at the putative
new cannabinoid receptor GPR-55 (Ryberg et al., 2009), and is an effective inhibitor of
FAAH, and thus indirectly increases AEA tone (Bisogno et al., 2001).

1.2.1 Cannabis use as a risk factor for schizophrenia
	
  
The link between cannabis use and an increased risk of developing schizophrenia is well
established in the scientific literature (Bossong & Niesink, 2010; Semple, 2005; Smit,
Bolier, & Cuijpers, 2004; Wilkinson, Radhakrishnan, & D’Souza, 2014). A seminal 1987
study established a correlation between lifetime prevalence of cannabis use and an
increased likelihood of developing schizophrenia later in life (Andersson et al., 1987).
Since then, numerous longitudinal studies have explored the nature of this relationship. In
general, the main findings demonstrate that while cannabis use alone is neither necessary
nor sufficient to induce psychotic disorders, prolonged and excessive use especially
during critical developmental periods of adolescence represents a significant risk factor in
individuals genetically and environmentally predisposed to developing psychotic
disorders and other mental illnesses (Wilkinson et al., 2014). Indeed, neuroimaging
studies have found that individuals who start using cannabis before 17 years of age show
reductions in cortical grey matter and increased percentage of white matter in comparison
to those who initiate use later (Wilson et al., 2000). Other imaging studies show that
chronic cannabis users also display reduced hippocampal and amygdalar volumes in
comparison to non-using controls (Yücel et al., 2008). Both cortical grey matter
reductions and structural abnormalities in hippocampal and amygdalar structures are
commonly observed pathophysiological features of schizophrenia (Ellison-Wright &
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Bullmore, 2009), however whether these neural alterations are a cause or effect of early
and extensive cannabis use has yet to be elucidated.
Additional evidence for the association between cannabis and schizophrenia
comes from challenge studies involving acute administration of Δ9-THC or other
cannabinoids, in healthy and schizophrenic individuals. In healthy volunteers, acute Δ9THC exposure has been shown to transiently induce a range of psychotomimetic
symptoms reminiscent of those observed in schizophrenia, including cognitive and
attentional impairments as well as feelings of paranoia and anxiety (Bhattacharyya et al.,
2012; Bhattacharyya et al., 2009a; D’Souza et al., 2012). In individuals with a confirmed
diagnosis of schizophrenia, treatment with Δ9-THC resulted in a transient exacerbation of
core psychotic symptoms, cognitive deficits and perceptual alterations (D’Souza et al.,
2005). Interestingly, studies investigating the effects of CBD show starkly opposite
results to those found with Δ9-THC treatment. In contrast to Δ9-THC, CBD
administration does not elicit any psychotomimetic effects, and is not associated with
perceptual alterations or cognitive deficits in healthy volunteers (Bhattacharyya et al.,
2009b). In individuals with schizophrenia, CBD actually displays antipsychotic efficacy
comparable to conventional antipsychotic medications (Leweke et al., 2012), likely due
to its ability to inhibit FAAH and indirectly elevated endogenous levels of AEA
(Giuffrida et al., 2004; Leweke et al., 1999).
The relationship between cannabis use and schizophrenia is thus complex and
further investigation is needed to elucidate the neurobiological mechanisms underlying
this association.

1.3 Research Purpose and Hypotheses
	
  
The studies reviewed above illustrate the central role of the eCB system in emotional
processing circuits, specifically within the mesocorticolimbic system, and describe how
dysfunctions in this system may represent a neurobiological mechanism that contributes
to the development of various neuropsychiatric disorders. However, little is known about
the role that CB1 receptor signaling within the NAcc plays in the processing of appetitive
and aversive emotional stimuli, specifically in response to phytocannabinoid
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administration. The work presented in this thesis attempts to address this, by pursuing the
following objectives:
Objective 1: To characterize the reinforcing properties of intra-NASh CBD
microinfusions in an unbiased conditioned place preference paradigm.
Objective 2: To characterize the behavioural effects of intra-NASh Δ9-THC and
CBD microinfusions during the encoding and recall of emotionally aversive
associative learning.
Based on clinical data, work from our own laboratory and the distinct pharmacological
profiles of Δ9-THC and CBD, I hypothesized that these two cannabinoid compounds
would exhibit dissociable and opposite effects in our behavioural paradigms.
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Chapter 2. Cannabidiol produces rewarding effects in the nucleus
accumbens shell via serotonergic and dopaminergic signaling
mechanisms
2.1 Introduction
Marijuana is the most widely used illicit drug in the world (Murray, Morrison, Henquet,
& Di Forti, 2007; United Nations, 2010) and although our understanding of
phytocannabinoids is growing, the debate over marijuana’s addiction potential and abuse
liability remains controversial. While traditionally not considered an addictive drug,
recent research suggests the presence of distinct marijuana dependence and withdrawal
syndromes in heavy users (Budney & Hughes, 2006; Ramesh, Schlosburg, Wiebelhaus,
& Lichtman, 2012).

However, cannabis contains over 70 known cannabinoid

compounds, each with unique pharmacological properties (ElSohly & Slade, 2005;
Radwan et al., 2009). Thus, the neuropsychopharmacological mechanism by which
cannabis, or its constituent compounds, elicits a behaviourally rewarding response
remains poorly understood.
Indeed, emerging clinical evidence suggests a functional dissociation between the two
main

pharmacological

components

of

cannabis,

the

psychoactive

Δ9-

tetrahydrocannabinol (Δ9-THC) and the non-psychoactive cannabidiol (CBD), in distinct
mesocorticolimbic substrates (Bhattacharyya et al., 2012; Bhattacharyya, Fusar-Poli, et
al., 2009a; Bhattacharyya et al., 2009b; Fusar-Poli et al., 2009). While Δ9-THC exhibits
propsychotic effects (Bhattacharyya et al., 2012), CBD displays antipsychotic (Leweke et
al., 2012; Mechoulam, Peters, Murillo-Rodriguez, & Hanus, 2007; Schubart et al., 2013;
Zuardi et al., 2012; Zuardi, Crippa, Hallak, Moreira, & Guimarães, 2006) and anxiolytic
(Almeida et al., 2013; Campos & Guimarães, 2008; Casarotto, Gomes, Resstel, &
Guimarães, 2010; Crippa et al., 2010; Fogaça, Reis, Campos, & Guimarães, 2014)
properties comparable to conventional antipsychotic medications.
Cannabinoids exert their neuropsychological effects by acting on the body’s
endocannabinoid (eCB) system at centralized cannabinoid CB1 receptors. Both Δ9-THC
and CBD resemble endogenous CB1R ligands, however their pharmacology is distinct.
Furthermore, in situ hybridization studies show high levels of colocalization between
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CB1 receptors and dopaminergic (DA) and serotonergic (5-HT) receptors, suggesting the
eCB system may play a crucial role in modulating activity of these systems (Hermann,
Marsicano, & Lutz, 2002; Maroteaux et al., 1992).
Until recently, research efforts have focused almost exclusively on determining the
reinforcing properties of Δ9-THC with mixed results (see Tzschentke, 2007 for a review).
Animal studies reveal rewarding and aversive effects of Δ9-THC in the conditioned place
preference and self-administration paradigms (Gardner, 2002; Tanda & Goldberg, 2003;
Valjent & Maldonado, 2000). However, there is little evidence that CBD itself possesses
hedonic properties (Parker, Burton, Sorge, Yakiwchuk, & Mechoulam, 2004). The aim of
the current study was to investigate the potential psychoactive properties of CBD in
discrete anatomical regions of the mesocorticolimbic circuitry. Specifically, we
conducted a series of behavioural pharmacological experiments examining the rewarding
effects of CBD microinfusions into the shell subdivision of the nucleus accumbens
(NASh), a structure which highly expresses CB1 receptors (Fusco et al., 2004;
Herkenham, Lynn, de Costa, & Richfield, 1991a; Moldrich & Wenger, 2000) and is
sensitive to synthetic cannabinoid reward in animal models (Mahler, Smith, & Berridge,
2007; Zangen, Solinas, Ikemoto, Goldberg, & Wise, 2006). We report here the first
evidence of the hedonic psychoactive properties of CBD in a conditioned place
preference paradigm.

2.2 Materials and Methods
2.2.1 Animals and Surgery
Male Sprague Dawley rats (300-350g) were obtained from Charles River Laboratories
(Quebec, CAN). Rats were anesthetized with an intraperitoneal (i.p.) injection of a
ketamine (80mg/ml)-xylazine (6mg/kg) mixture and meloxicam (1.0 mg/kg; s.c.) was
administered preoperatively in order to reduce pain and post-surgical inflammation.
Following an assessment of anesthetic depth, rats were immobilized using a Kopf
stereotaxic device. Using sterile technique, an incision was made to expose the skull.
Guide cannulae (22-gauge) were implanted bilaterally into the NASh using flat skull
stereotaxic coordinates as follows (12o angle, in mm from bregma): anteroposterior (AP)
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+ 1.8, lateral (LAT) ± 2.6, ventral (V) -7.4 from the dural surface. Cannulae were
implanted in the VTA using the following stereotaxic coordinates (10o angle, in mm from
bregma): anteroposterior (AP) + 1.8, lateral (LAT) ± 2.6, ventral (V) -8.0 from the dural
surface. All stereotaxic coordinates were based upon the atlas of Paxinos and Watson
(1996). Cannulae were secured to the skull using four small jeweler’s screws and dental
acrylic. Dust-caps were used to ensure the patency of the cannulae. All procedures were
performed in accordance with the Canadian Council on Animal Care (CCAC) and were
approved by Western University’s Council on Animal Care.

2.2.2 Post-Surgery SOP
Rats were injected subcutaneously with 3 – 10 mL of physiological saline in order to
prevent dehydration. Rats recovered in a clean home cage filled with wood shavings and
warmed under a heat lamp. Behaviour was monitored until recovery from the anesthetics
and sternal recumbency attained. A maintenance dose of meloxicam (1.0 mg/kg) was
administered (s.c.) 24 hours post-surgery in order to reduce pain and inflammation.
Following at least one week of recovery, rats were then tested in behaviorual paradigms.

2.2.3 Conditioned Place Preference
All rats were conditioned using an unbiased, fully counterbalanced conditioned place
preference (CPP) procedure, as described previously (Laviolette & van der Kooy, 2003;
Laviolette, Nader, & van der Kooy, 2002). Rats received drug microinfusions, and were
then conditioned in one of two environments that differed in colour, texture and scent.
One environment was black constructed with a smooth Plexiglas floor, wiped down with
2% acetic acid solution before each conditioning session. The other environment was
white with a wire mesh floor covered with wood chips. Rats display no baseline
preference for either of these two environments (Laviolette & van der Kooy, 2003). Rats
were preconditioned (24 hrs prior to conditioning) in a motivationally neutral grey box
for 30 min, in order to minimize stress during behavioural conditioning. Immediately
prior to conditioning, rats received intra-NASh microinfusions of CBD (50, 100,
500ng/0.5µl) alone, or coadministered with the DA antagonist α-flupenthixol (100ng –
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1.0µg/0.5µl), 5-HT1A antagonist NAD-299 hydrochloride (100 – 500ng/0.5µl), or 5-HT1B
antagonist GR-55562 (10 – 100ng/0.5µl). For animals implanted with cannulae in the
NASh and the VTA, the GABAA antagonist bicuculline methiodide (50ng/0.5µl) and the
GABAB antagonist hydroxysaclofen (100ng/0.5µl), or their respective vehicle, were
coadministered into the VTA 2 min prior to intra-NASh CBD infusion.
Following microinfusions, rats were placed in one of the two conditioning
environments for 30 min. Experimental treatments were counterbalanced such that each
animal was randomly assigned to receive either drug or vehicle infusions in either the
white or the black environment. During conditioning, rats received four drugenvironment and four saline-environment conditioning sessions. During testing, rats were
placed on a narrow, neutral grey zone separating the two test environments and times
spent in each environment was digitally recorded and scored separately for each animal
over a 10 min test session. All rats were tested in a drug free state.

2.2.4 Drug administration
The broad-spectrum DA receptor antagonist, α-flupenthixol, the highly specific 5-HT1B
receptor antagonist, GR-55562, the GABAA antagonist, bicuculline methiodide, and the
GABAB antagonist, hydroxysaclofen, were dissolved in physiological saline (pH adjusted
to 7.4). The 5-HT1A receptor antagonist, NAD-299 hydrochloride, and CBD were
dissolved in dimethyl sulfoxide (DMSO, Fisher Scientific). For NASh and VTA
microinfusions, stainless steel guide cannulae (22-gauge) were implanted bilaterally into
the NASh through a 28-gauge microinfusion injector (Plastics One). Bilateral
microinfusions were performed over 1 min through a Hamilton microsyringe. In order to
ensure the diffusion of the drug away from the injector tip, the internal cannulae were left
in place for an additional minute. All drugs were purchased from Tocris Biosciences.

2.2.5 VTA neuronal activity recording
In vivo single-cell extracellular recordings in the VTA were performed as
described previously (Tan, Bishop, Lauzon, Sun, & Laviolette, 2009). Briefly, 18 rats
were anesthetized with urethane (1.4 g/kg, i.p.) and placed in a stereotaxic frame with
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body temperature maintained at 37°C. A scalp incision was made and a hole was drilled
in the skull above the NASh and the VTA. For intra-NASh microinfusion of CBD (100
ng/ 0.5 µL), a 1 µL Hamilton syringe was slowly lowered at the same coordinates used
for behavioral studies. For intra-VTA extracellular recording, glass micro-electrodes
(with an average impedance of 6-8 MΩ) filled with a 2% Pontamine Sky Blue solution
were lowered using a hydraulic micro-positioner (Kopf 640) at the following flat skull
stereotaxic coordinates (in mm from bregma): anteroposterior (AP) -5.3, lateral (LAT) ±
0.7 from midline, ventral (V) -7.0 to -8.5 from the dural surface. Extracellular signals
were amplified using a MultiClamp 700B amplifier (Molecular Devices) and recorded
through a Digidata 1440A acquisition system (Molecular Devices) using pClamp 10
software. Extracellular recordings were filtered at 1 kHz and sampled at 5 kHz. VTA DA
neurons were identified according to well-established electrophysiological features
(Jalabert et al., 2011; Ungless, Magill, & Bolam, 2004): (1) a relatively long action
potential width (>2.5 ms); (2) a slow spontaneous firing rate (2 - 5 Hz) (3) a triphasic
waveform consisting of a notch on the rising phase followed by a delayed after potential;
and (4) a single irregular or bursting firing pattern. VTA GABA interneurons were also
characterized based upon previously reported criteria: (1) a narrow action potential width
(<1 ms), (2) a biphasic waveform; (3) relatively fast firing rates (typically between 10 and
20 Hz); and (4) the absence of bursting activity. Neurons that failed to clearly meet the
aforementioned criteria for VTA DA or VTA non-DA electrophysiological neuronal
properties were excluded from further study.
Recordings analyses were accomplished using the Clampfit 10 software package.
The response patterns of isolated VTA neurons to intra-NASh CBD microinfusions were
determined by comparing the neuronal frequency rates between the 5 min pre-infusion
versus post-infusion epochs. Classification of drug-infusion effects used a criterion of a ≥
10% increase in firing frequency post-infusion to be classified as an “increase” effect; a ≤
10 % decrease to be classified as a “decrease” effect. Neurons showing firing frequency
parameters within these cut-off points were classified as “no change”. Within identified
VTA DA neurons, we also analyzed the burst rate (number of burst events over time) and
the number of spikes within each burst. The onset of a burst was defined as the
occurrence of two consecutive spikes with an inter-spike interval of <80 ms.
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For histological analysis of extracellular VTA neuronal recording sites, recording
electrode positions were marked with an iontophoretic deposit of Pontamine Sky Blue
dye (−20 µA, continuous current for 12–15 minutes).

Then, rats were perfused

transcardially with isotonic saline followed by 10% formalin. Brains were removed and
stored in a 25% sucrose-formalin solution before sectioning (40 µm sections) on a
freezing cryostat. Following this, sections were stained with cresyl violet and infusion
and/or neuronal recording sites were confirmed with light microscopy.
2.2.6 Histology
Following completion of experiments, rats were transcardially perfused, brains were
extracted and stored in a specimen vial containing formalin with 25% sucrose solution for
at least 24hrs. The region of the projected cannulae placements were cut into 40 µm
coronal sections, mounted and stained using cresyl violet to allow for histological
examination of the injection site. The majority of NASh and VTA placements were
localized within the region of the shell of the nucleus accumbens or the ventral tegmental
area, respectively. Rats found to have injectors situated outside the anatomical boundaries
of the NASh or VTA were excluded from experimental analysis.

2.2.7 Data analysis
Behavioural data were analyzed with a multivariate ANOVA followed by pairedsamples t-tests or Fisher’s Least Significant Difference (LSD) tests, where appropriate.
Electrophysiological data were analyzed using a paired-sampled t-test (SPSS Statistics 21
software) and only values with p ≤ 0.05 were considered as significant.
	
  

2.3 Results	
  
2.3.1 Histological analysis
Histological analysis revealed microinfusion injector cannulae placements to be
bilaterally localized within the anatomical boundaries of the shell subdivision of the
nucleus accumbens and the VTA, according to the Rat Brain Atlas (Paxinos & Watson,
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1996). Figure 1A presents a microphotograph displaying a typical injector placement
within the NASh. Figure 1B displays a schematic illustration showing representative
intra-NASh bilateral cannuale placements along the rostral-caudal axis of the nucleus
accumbens. Figure 1C shows a microphotograph displaying a typical injector placement
within the VTA. Figure 1D displays a schematic illustration showing representative intraVTA bilateral cannuale placements along the rostral-caudal axis of the ventral tegmental
area. Rats with cannulae placements located outside of the NASh or VTA were removed
from data analysis.
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Figure 1. Histological analysis of intra-NASh and intra-VTA microinjection sites. A,
Microphotograph of a representative injector placement within the shell subdivision
(AcbSh) of the NAcc. B, Schematic representation of select intra-NASh injector
locations; • = 100ng CBD group, ♦ = 100ng CBD + 500ng NAD299 group. C,
Microphotograph of a representative injector placement in the VTA. D, Schematic
representation of intra-VTA injector locations; ο = 100ng saclofen + 50ng bicuculline.

2.3.2 Intra-NASh CBD microinfusions display behaviourally rewarding properties
In order to establish a dose-response curve to examine the motivational properties of
CBD, we performed a conditioned place preference experiment using a range of doses of
CBD, 50ng (n = 8), 100ng (n = 8), 500ng (n = 6). Multivariate ANOVA revealed a
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significant effect of treatment, F(4, 36) = 3.38, p = .019. Follow-up paired samples t-tests
revealed that rats spent significantly more time, t(7) = -5.45, p = .001, in the environment
paired with 100ng CBD microinfusion (M = 284.10s, SD = 32.99) than the environment
paired with vehicle administration (M =172.24s, SD = 42.83). In contrast, there were no
significant differences in the amount of time rats spent in the CBD or vehicle-paired
environments for the 50ng dose, t(7) = 0.47, p = .66, or the 500ng dose, t(5) = -0.38, p =
.72 (see Figure 2).
Based upon this dose-dependent effect, we chose the highest behaviourally effective dose
(i.e., 100ng/0.5µl) of CBD for subsequent behvioural experiments. For the sake of
simplicity, data from all follow-up experimental groups will be compared to the data of
our 100ng CBD group.
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Figure 2. Dose response curve for intra-NASh CBD microinjections. Data represent
mean (±SEM) time spent in drug- and vehicle-paired environments for rats
conditioned with intra-NASh CBD. A moderate dose of 100ng/0.5µl CBD produces a
significant conditioned place preference for the drug-paired environment, suggesting that
CBD has reinforcing properties in moderate doses.
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2.3.3 Intra-NASh 5-HT1A receptor blockade switches the motivational valence of
CBD from rewarding to aversive
Based on the large body of evidence that implicates the serotonergic system, particularly
5-HT1A receptors, in the pharmacological action of CBD we challenged our observed
place preference effect with intra-NASh NAD-299 hydrochloride, a potent 5-HT1A
antagonist. Multivariate ANOVA revealed a significant effect of treatment, F(6, 46) = 3.29,
p = .009. Follow-up paired samples t-tests revealed that 100ng NAD-299 (n = 7) was
effective at blocking the place preference induced by CBD (100ng), t(6) = 0.90, p = .40.
At the higher dose of 500ng NAD-299 (n = 6), 5-HT1A antagonism switched CBD’s
motivational valence from rewarding to aversive, t(5) = 2.682, p = .044, rats receiving coadministration of CBD with 500ng NAD-299 spent significantly more time in the
vehicle-paired environment (M = 327.70s, SD = 67.17) than the CBD-paired environment
(M = 182.07s, SD = 70.29) (see Figure 3A). In order to rule out the possibility that NAD299 may possess aversive properties on its own, we performed a control experiment in
which rats were conditioned with vehicle or 100ng NAD-299 (n = 7). Paired samples ttest revealed that rats did not form a significant preference or aversion for either the
vehicle- (M = 224.09s, SD = 167.89) or NAD-299 (M = 301.03s, SD = 168.74) -paired
environments, t(6) = -0.607, p = .57, suggesting that NAD-299 alone is not responsible
for the conditioned aversion observed with rats receiving 500ng NAD-299 in
combination with CBD. (see Figure 3A). Post hoc analysis using Fisher’s LSD revealed
that rats conditioned with 100ng CBD co-administered with 100ng and 500ng NAD-299
spent significantly (p’s < .05) more time in the vehicle-paired environment (M100ng NAD =
310.53s, SD100ng NAD = 146.71; M500ng NAD = 327.70s, SD500ng NAD = 67.17) compared to rats
conditioned with 100ng CBD alone (M = 172.24, SD = 42.83).

2.3.4 Intra-NASh 5-HT1B receptor antagonism blocks the acquisition of CBD reward
memory
Given our results with 5-HT1A receptor antagonism, and based upon evidence showing
that CB1 receptors are colocalized with 5-HT1B receptors, we next examined whether
blockade of intra-NASh 5-HT1B receptors would yield similar results. In a separate
experiment, rats were conditioned with CBD (100ng) co-administered with GR-55562
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dihydrochloride, a potent 5-HT1B antagonist. Multivariate ANOVA revealed a significant
effect of treatment, F(4, 36) = 3.29, p = .021. Follow-up t-tests revealed that intra-NASh 5HT1B antagonism was effective at blocking CBD-induced place preference at a dose of
10ng (n = 7), t(6) = 0.558, p = .60, and 100ng (n = 7), t(6) = -0.176, p = .87. Post hoc
analysis using Fisher’s LSD revealed that rats conditioned with 100ng CBD coadministered with 10ng GR-55562 spent significantly (p = .044) more time in the
vehicle-paired environment (M = 290.53s, SD = 141.23) compared to rats conditioned
with 100ng CBD alone (M = 172.24, SD = 42.83) (see Figure 3B). Together, these data
suggest that serotonergic transmission at both 5-HT1A and 5-HT1B receptors is necessary
for the behaviourally hedonic properties of CBD.

A)

B)

	
  
Figure 3. Intra-NASh 5-HT antagonism blocks CBD reward memory acquisition. A,
Intra-NASh 5-HT1A antagonism with 100ng/0.5µl NAD299 is sufficient to block
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acquisition of CBD reward memory, while 500ng/0.5µl NAD299 switches CBD’s
motivational valence from rewarding to aversive. Intra-NASh NAD299 alone does not
produce a preference or an aversion. B, Intra-NASh 5-HT1B antagonism (10ng and
100ng/0.5µl) is sufficient to block acquisition of intra-NASh CBD reward memory.

2.3.5 Intra-NASh DA receptor antagonism blocks the acquisition of CBD reward
memory
Given that most drugs of abuse evoke phasic DA release from the VTA, we challenged
our behaviourally effective dose of CBD (100ng) with α-flupenthixol (α-flu), a broad
spectrum DA antagonist, in order to block signaling from DAergic VTA projections to
the NASh. Although CBD is not known to interact with the DAergic system, multivariate
ANOVA revealed a significant effect of treatment, F(4, 46) = 6.93, p = .00. Follow-up ttests revealed that intra-NASh DA antagonism was effective at blocking CBD-induced
place preference at a dose of 100ng (n = 9), t(8) = -1.26, p = .24, and 1.0µg (n = 10), t(9) =
-1.06, p = .32. Rats conditioned with CBD co-administered with 100ng or 1.0µg α-flu
did not develop significant preferences for either the CBD- or vehicle-paired
environments (see Figure 4). Thus, the data suggest that acquisition of CBD reward
memory is dependent on intra-NASh DAergic transmission, presumably originating from
VTA projections.

Figure 4. Intra-NASh DA antagonisms blocks acquisition of CBD reward meory. Intra-NASh
DA antagonism with α-flupenthixol (100ng and 1.0µg/0.5µl) is sufficient to block acquisition of
intra-NASh CBD reward memory.
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2.3.6 Intra-NASh CBD decreases DAergic neuronal activity in the VTA
In order to test the hypothesis that intra-NASh CBD elicits phasic increases in VTA DA
release, we performed in vivo electrophysiology experiments in which the rewarding dose
of CBD (100ng) was microinfused into the NASh while simultaneously recording singlecell extracellular neuronal activity in the VTA. A total of 15 VTA-DA neurons were
recorded and analyzed following intra-NASh CBD microinfusion. A cell was considered
to have changed its firing rate if there was a minimum of 10% difference from baseline.
According to this criterion, 60% (n = 9) of DA neurons showed a decrease in activity, 7%
(n = 1) showed an increase, and 33% (n = 5) demonstrated no change in activity levels.
Statistical analyses of the average frequency recorded during the 5min before and 5min
after the intra-NASh microinfusion showed that CBD significantly decreased the activity
of VTA DA neurons (t(14) = 3.13, p < 0.01). Furthermore, bursting analysis revealed that
CBD significantly reduced the number of burst events over time (t(14) = 2.76, p < 0.05)
without significantly decreasing the number of spikes within each burst (t(14) = 2.06, p =
0.06) (see Figure 5). Taken together, these data suggest that CBD (100 ng) microinfused
in the NASh induces an inhibition of VTA-DA neuronal activity. The reduction of the
firing frequencies and burst events suggest that the tonic and phasic release of DA in the
NASh are reduced following the microinfusion of CBD.
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Figure 5. Intra-NASh CBD decreases DAergic neuronal activity in the VTA. A,
Representative rastergram showing firing frequency patterns of sampled VTA DAergic
neurons during intra-NASh CBD microinfusion. VTA DAergic neuronal recording
sample demonstrates a typical decrease in neuronal activity following intra-NASh CBD
(100ng/0.5µl). B, Number of DAergic cells sampled, 60% of cells decreased neuronal
activity, 33% displayed no change in activity, and 7% exhibited an increase in activity. C,
Frequency (Hz) of VTA DAergic cell firing before and after intra-NASh microinfusion.
Following CBD administration, cells display a significant reduction in firing frequency.
D, Number of burst events per minute of VTA DAergic cells before and after intra-NASh
CBD microinfusion. Following CBD administration, there is a significant reduction in the
number of burst events per minute.

2.3.7 Intra-NASh CBD modulates GABAergic neuronal activity in the VTA
We found that CBD (100ng) was able to significantly decrease VTA DAergic neuronal
activity. GABA interneurons are one of the major sources of inhibitory neurotransmitters
within the VTA and are known to control reward signaling between DAergic and non	
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DAergic neural motivational systems (Laviolette & van der Kooy, 2001). As a result, it is
highly probable that the observed CBD effect on VTA DAergic cell activity was due to
an increase in VTA GABA interneuron activity. To test this hypothesis, we recorded and
analyzed VTA GABA neurons (n = 15) before and after a microinfusion of CBD (100
ng) into the NASh. Analysis of the general activity changes revealed that 27% (n = 4) of
interneurons decreased their activity, 40% (n = 6) of interneurons increased their activity,
and 33% (n = 5) demonstrated no change in activity levels. Statistical analyses of the
frequencies recorded during the 5 min before and 5 min after the intra-NASh
microinfusion showed that CBD did not significantly modify the average firing frequency
of VTA GABA interneurons, t(14) = -0.04; p = 0.97. Collectively, these data suggest that
CBD microinfused in the NASh induce heterogeneous effects on VTA GABA cells (see
Figure 6). However, the majority of interneurons (40%) increased their firing. Therefore,
it seems reasonable that the effect of CBD on VTA DAergic neuronal activity was
attributable to the sub-population of GABA cells that increased their firing frequency.
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Figure 6. Intra-NASh CBD modulates GABAergic interneuron neuronal activity in
the VTA. A, Representative rastergram showing firing frequency patterns of sampled
VTA GABAergic neurons during intra-NASh CBD microinfusion. VTA GABAergic
neuronal recording sample demonstrates a typical decrease in neuronal activity following
intra-NASh CBD (100ng/0.5µl). B, Representative rastergram showing firing frequency
patters of sampled VTA GABAergic neurons during intra-NASh CBD microinfusion.
VTA GABAergic neuronal recording sample demonstrates a typical increase in neuronal
activity following intra-NASh CBD (100ng/0.5µl). C, Number of GABAergic cells
sampled, 27% of cells decreased neuronal activity, 33% displayed no change in activity,
and 40% exhibited an increase in activity. D, Frequency (Hz) of VTA GABAergic cell
firing before and after intra-NASh microinfusion. Following CBD administration, the
subpopulation of cells that demonstrated an increase in neuronal activity displayed a
significant increase in firing frequency following intra-NASh CBD.
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2.3.8 Intra-VTA GABAA/B receptor antagonism blocks the acquisition of intraNASh CBD reward memory
In order to further investigate the effects of CBD’s modulation of VTA GABAergic
activity at the behavioural level, we performed experiments in which rats were bilaterally
implanted with cannulae into both the NASh and VTA. Rats received infusions of intraNASh CBD (100ng) and a combination of intra-VTA bicuculline (50ng) and saclofen
(100ng) in order to antagonize both GABAA and GABAB receptors in the VTA. Rats
were then conditioned in the CPP protocol outlined above. A paired samples t-test
revealed intra-VTA GABAA/B antagonism blocked the acquisition of intra-NASh CBD
reward memory, t(8) = 1.42, p =.195. Rats did not spend significantly more time in the
CBD-paired environment (M = 209.95, SD = 139.32) compared to the vehicle-paired
environment (M = 343.41, SD = 145.03). An independent samples t-test revealed that
rats conditioned with intra-VTA GABAA/B antagonists spent significantly more time in
the vehicle-paired environment (M = 343.41, SD = 145.03) compared to rats conditioned
with intra-NASh CBD alone (M = 172.24, SD = 42.83), t(15) = -3.379, p = .007. In
contrast independent samples t-test revealed that rats conditioned with intra-VTA
GABAA/B antagonists did not spend significantly more time in the drug-paired
environment (M = 209.95, SD = 139.32) compared to rats conditioned with intra-NASh
CBD alone (M = 284.10, SD = 32.99), t(15) = 1.55, p = .156. These data indicate that
antagonism of VTA GABAA/B receptors blocks the acquisition of intra-NASh CBD
reward memory (Figure 7). Together with our electrophysiology data, these results
suggest that a reduction in VTA DAergic signaling due to a general increase in VTA
GABAergic interneuron activity is necessary for the acquisition of intra-NASh CBD
reward memory. By blocking GABAA/B receptors in the VTA, GABA interneurons are
unable to suppress DAergic projection neurons to the NASh. Thus, the intra-NASh CBDinduced decrease in VTA DAergic activity is blocked, and the behavioural reward effect
is abolished.
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Figure 7. Intra-VTA GABAA/B antagonism blocks acquisition of intra-NASh CBD
reward memory. Intra-VTA antagonism of GABAA receptors, with bicuculline
(50ng/0.5µl), and GABAB receptors, with saclofen (100ng/0.5µl), is sufficient to block
acquisition of intra-NASh CBD reward memory.

2.4 Discussion	
  
This work represents the first demonstration that cannabidiol does indeed possess
reinforcing psychoactive properties in the shell of the nucleus accumbens (NASh) at both
the behavioural and electrophysiological levels. Intra-NASh CBD microinfusions
produced a significant place preference reward memory in an unbiased CPP paradigm.
This effect was dependent on 5-HT1A, 5-HT1B and DA receptor signaling within the
NASh, and elicited a modulation of DAergic and GABAergic neuronal activity within the
VTA.
	
  

2.4.1 Intra-NASh CBD produces a reward memory in a dose-dependent manner	
  
The conditioned place preference paradigm is an animal model for investigating the
rewarding or aversive properties of various chemical compounds. It has particular utility
when examining the effects of drugs of abuse, because of the many parallels it shares
with human drug use. Both humans and animals will seek out environmental cues that
have been associated with drug administration and for many addicts coming into contact
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with cues that predict drug use (e.g., drug paraphernalia, a particular spatial location
where drugs were used), can be major contributing factors to relapse (Carter & Tiffany,
1999; Young et al., 2014). In addition, many drugs of abuse, such as nicotine (Laviolette
& van der Kooy, 2004; Tan et al., 2009), alcohol (Philpot, Badanich, & Kirstein, 2003),
and cannabinoids (Katsidoni, Kastellakis, & Panagis, 2013), exhibit dose-dependent
effects in animal models such as CPP. 	
  
The current study is the first to systematically establish a dose-response curve for
the rewarding properties of CBD using a CPP paradigm. Our results show that while very
low (50ng) and very high (500ng) doses of CBD did not produce any appetitive or
aversive effects, a moderate dose of CBD (100ng) produced a significant preference for
the environment paired with intra-NASh CBD microinfusions (Figure 2). These data
suggest that CBD does possess hedonic psychoactive properties and may give us insight
into the behavioural and cellular mechanisms that precipitate and maintain cannabis
abuse.	
  
	
  

2.4.2 CBD reward signals through 5-HT receptor transmission in the NASh 	
  
In addition to its antagonistic action at CB1 receptors, CBD has been shown to have
agonistic properties at serotonin (5-HT) receptors, particularly at 5-HT1A receptors
(Russo et al., 2005). We therefore performed experiments to investigate whether the
observed rewarding effect of CBD was dependent on 5-HT1A receptor transmission
within the NASh. We found that co-administration of CBD with NAD-299, a 5-HT1A
receptor antagonist, was able to block CBD reward memory acquisition at the low dose
(100ng). However, at the high dose (500ng), 5-HT1A receptor antagonism switched
CBD’s motivational valence from rewarding to aversive (Figure 3A). Together these data
suggest that 5-HT1A signaling is crucial for the hedonic properties of intra-NASh CBD,
and that a decrease in 5-HT1A signaling may precipitate an aversive response. Recent
studies implicate the 5-HT1A receptor as playing a critical role in the anxiolytic,
antidepressant and antipsychotic actions of CBD (Almeida et al., 2013; Campos &
Guimarães, 2008; Campos, Ferreira, & Guimarães, 2012; De Almeida & Mengod, 2008;
Fogaça et al., 2014; Zanelati, Biojone, Moreira, Guimarães, & Joca, 2009). Interestingly,
deficits in 5-HT signaling have been implicated in a number of neuropsychiatric disorders
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including anxiety, depression and addiction (see Gingrich & Hen, 2001 for a review).
Indeed, mice lacking the 5-HT1A receptor display altered emotional states and reactivity
to environmental cues (Zhuang et al., 1999). Furthermore, 5-HTergic neurotransmission
through 5-HT1A receptors has been suggested to modulate brain reward processes
(Harrison & Markou, 2001), and CBD has been shown to inhibit synaptic transmission in
the hippocampus through 5-HT1A receptors (Ledgerwood, Greenwood, Brett, Pratt, &
Bushell, 2010). Together, these data suggest that 5-HT1A receptor transmission may be
required for the accurate processing of emotional and motivational information. It is
therefore possible that antagonism of 5-HT1A receptors in our study prevented CBD from
exerting the full range of its psychopharmacological effects. Another possibility is that 5HT1A antagonism alone produced an aversive response. However this seems unlikely, as
rats conditioned with NAD-299 alone did not develop a significant aversion to the
environment paired with NAD-299 administration. Furthermore, 5-HT1A antagonism is
not known to produce either appetitive or aversive effects in the CPP paradigm (Risinger
& Boyce, 2002). 	
  
The 5-HT1B receptor is another well-characterized 5-HT receptor subtype and like
the 5-HT1A receptor, it has been implicated in a number of physiological functions and
neuropsychiatric disorders (Sari, 2004; Ujike et al., 2011). Furthermore, 5-HT1B receptors
are highly co-expressed with CB1 receptors in the striatum (Hermann et al., 2002;
Maroteaux et al., 1992) suggesting a modulatory role of this receptor in motivational and
emotional processing. Based on this information, we performed a separate experiment to
examine whether the rewarding effect of CBD was dependent on 5-HT1B receptor
signaling. We found that intra-NASh co-administration of CBD with GR-55562, a 5HT1B receptor antagonist, was able to block CBD reward memory acquisition (Figure
3B). Previous studies have found that 5-HT1B receptors are expressed at the nerve
terminals of GABAergic projection neurons from the nucleus accumbens to the VTA as
well as DAergic projection neurons from the VTA to the nucleus accumbens (Boschert,
Amara, Segu, & Hen, 1994; Bruinvels et al., 1994; Maroteaux et al., 1992; Sari, 2004;
Voigt, Laurie, Seeburg, & Bach, 1991). Additionally, both the NASh and the VTA are
heavily innervated by serotonergic projections (Lavoie & Parent, 1990; Phelix &
Broderick, 1995), implicating the serotonergic system as a critical modulator of brain
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reward pathways. Given that 5-HT1B receptors are inhibitory G-protein coupled receptors,
it is possible that antagonism of the receptor inhibited the ability of DAergic projection
neurons from the VTA to be modulated by endogenous 5-HT, thereby raising the overall
DAergic tone in the NASh. In light of our electrophysiology results (discussed below)
that indicate that intra-NASh CBD microinfusions result in a decrease in VTA DAergic
neuronal activity, it is possible that artificially elevating NASh DAergic tone abolishes
the behaviourally rewarding effect of CBD, which may depend on reduced NASh DA
originating from the VTA. Together, the results suggest that 5-HT receptor signaling may
play a crucial role in the rewarding effects of cannabinoids in general, and of CBD in
particular. 	
  
	
  

2.4.3 CBD reward signals through DA receptor transmission in the NASh 	
  
Given that most drugs of abuse elicit increased DA release from the VTA, which
reinforces drug use behaviours (Adinoff, 2004; Laviolette & Grace, 2006; Margolis,
Lock, Hjelmstad, & Fields, 2006), we performed separate experiments in order to
investigate whether the behaviourally rewarding dose of CBD (100ng) was dependent on
DAergic signaling within the NASh. We found that co-administration of CBD with αflupenthixol (100ng, 1.0µg), a DA receptor antagonist, was sufficient to block the
acquisition of intra-NASh CBD reward memory (Figure 4).

	
  

Previous studies have found DA receptor antagonism, using α-flupenthixol, to be
effective at blocking the acquisition of drug reward memory in the CPP procedure
(García Horsman & Paredes, 2004). Given that the NASh receives DAergic input from
the VTA (Ferreira, Del-Fava, Hasue, & Shammah-Lagnado, 2008; Ikemoto, 2007), it is
highly probable that our intra-NASh DA receptor antagonism prevented increased
DAergic reward signals from the VTA and thus blocked the acquisition of intra-NASh
CBD reward memory.

	
  

	
  

2.4.4 CBD modulates intra-VTA DA and GABA neuronal activity	
  
In order to elucidate the mechanism of intra-NASh CBD reward in greater detail, we
performed single unit in vivo electrophysiology experiments in which rats received CBD

	
  

32	
  

	
  
(100ng/0.5µl) microinfusion into the NASh while we simultaneously recorded single cell
neuronal activity in the VTA. Given that drugs of abuse elicit phasic DA release from the
VTA, and that we were successful in blocking intra-NASh CBD reward memory
acquisition using DA receptor antagonists, we predicted that our behaviourally effective
dose of CBD (100ng) would elicit a similar increase in DAergic neuronal activity in the
VTA, providing a mechanism to explain the rewarding effect observed in the CPP
experiments. Contrary to our hypothesis, the majority of DA cells sampled showed a
significant decrease in neuronal activity as measured by a decrease in firing frequency
(Fig. 5C) and a decrease in the number of burst events per minute (Fig. 5D). Of the nonDA neurons (presumably GABAergic interneurons) sampled, we observed a trend
towards increased neuronal activity as measured by an increase in firing frequency (Fig.
6B). Of the subpopulation of neurons exhibiting increased activity, there was a significant
increase in firing frequency following intra-NASh CBD microinfusion (Fig. 6D). In
contrast, only a small sample of non-DA neurons showed a decrease in firing frequency
(Fig. 6A). It is therefore highly probable that the observed decrease in DAergic activity is
due to the increased inhibitory influence of GABAergic interneurons that modulate the
activity of DAergic projection neurons to the NASh and other mesocorticolimbic
structures. 	
  
Based on these results, we performed a separate experiment in which rats received
bilateral cannulae implantations into the NASh as well the VTA, in order to examine
whether intra-NASh CBD reward was dependent on intra-VTA GABAergic signaling.
We found that antagonism of both GABAA and GABAB receptors in the VTA was
sufficient to block the acquisition of intra-NASh CBD reward memory (Figure 7).
Together with the results from our electrophysiology experiments, these data suggest that
modulation of DAergic activity by GABAergic interneurons is critical for the acquisition
of intra-NASh CBD reward memory. These results seem at odds with the results of our
behavioural experiment using DA antagonists, which suggested that intra-NASh DA
signaling was necessary for the behavioural expression of CBD reward. It is possible that
while intra-VTA DAergic neuronal activity was significantly reduced following intraNASh CBD microinfusion, the reduced VTA DA signals were still necessary for the
acquisition of intra-NASh CBD reward memory. Thus, by blocking intra-NASh DA
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receptors, we had prevented the VTA from being able to send reward-related DA signals
to the NASh.

	
  

Many recent research efforts have focused on elucidating the mechanism by
which CBD may exert its antipsychotic properties (Mechoulam et al., 2007). One recent
study (Leweke et al., 2012) suggests that the ability of CBD to prevent the degradation of
the endocannabinoid anandamide may be at least partially responsible for CBD’s
antipsychotic efficacy. In the present study, we present evidence that CBD can modulate
mesolimbic DA activity by decreasing DAergic activity in the VTA. Given that
mesolimbic DA hyperactivity has been implicated as a major etiological factor in a
number of neuropsychiatric disorders including addiction and schizophrenia (Laviolette
& Grace, 2006; Mehler-Wex, Riederer, & Gerlach, 2006), these data represent another
possible pharmacological mechanism that may be responsible for CBD’s antipsychotic
actions.	
  

2.5 Summary	
  
This study presents the first evidence for hedonic properties of CBD, long believed to be
devoid of reinforcing effects. Our results support past research showing that cannabinoids
have a diverse range of pharmacological effects including interactions with the
serotonergic, DAergic and GABAergic neurotransmitter systems. Our electrophysiology
results lend further credence to the notion that cannabinoids are unique in the world of
abused drugs as CBD actually drives inhibition of VTA DAergic transmission. Future
studies should examine the electrophysiological changes induced by 5-HT1A receptor
antagonism on VTA neuronal activity in order to determine the mechanism that switches
CBD’s motivational valence from rewarding to aversive.
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Chapter 3. Cannabidiol and Δ9-tetrahydrocannbinol differentially
modulate the acquisition of an associative fear memory in the
nucleus accumbens shell	
  
	
  

3.1 Introduction

	
  
Dysfunction in emotional and motivational information processing is a hallmark of the
cognitive deficits observed in schizophrenia. This can manifest as abnormal social
cognition and impaired emotional expression, and may lead to aberrant salience
attribution to what would normally be insignificant sensory experiences or events. In the
extreme, such attribution may lead to psychotic ideation and persistent maladaptive
behaviours (Laviolette & Grace, 2006). Cannabinoids can produce similarly profound
effects on emotional information processing and sensory perception (D’Souza et al.,
2005) by acting on centralized CB1 receptors. Acute cannabinoid exposure can lead to
paranoid thought processes, anxiety and agitation even among healthy individuals and
may precipitate episodes of psychosis in individuals predisposed to psychotic disorders
(Bhattacharyya et al., 2012). Several neural structures comprise the emotional processing
circuitry, collectively referred to as the mesocorticolimbic system. These areas contain
high levels of dopamine (DA) and CB1 receptors, which are critical in emotional salience
processing. Furthermore, both of these neurotransmitter systems have been implicated in
the etiology and neuropathological profile of schizophrenia (Eggan, Hashimoto, & Lewis,
2008; Lauzon, Bishop, & Laviolette, 2009; Laviolette & Grace, 2006; Scatton & Sanger,
2000), and structural and functional abnormalities in mesocorticolimbic structures have
been reported in patients with schizophrenia (Burns et al., 2003; Crespo-Facorro et al.,
2001; Taylor, Liberzon, Decker, & Koeppe, 2002). Abnormalities in endocannabinoid
signaling in particular have been implicated in the aberrant emotional processing
observed in psychosis (Dalton, Long, Weickert, & Zavitsanou, 2011; Hall, Degenhardt, &
Teesson, 2004), and there is also a growing body of evidence which supports the link
between excessive marijuana exposure, especially during adolescence, and an increased
risk of developing schizophrenia-related psychoses in later adulthood (Bossong &
Niesink, 2010; Semple, 2005; Smit et al., 2004).
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However, marijuana smoke represents a complex mixture of chemical
components, possessing dissociable psychoactive and pharmacological properties
(ElSohly & Slade, 2005; Radwan et al., 2009). While Δ9-THC may precipitate, or even
exacerbate psychotic symptoms, CBD has been shown to have antipsychotic and
anxiolytic properties (Bhattacharyya, et al., 2009b).
The goal of the current study was to investigate the effects of CBD and Δ9-THC
on the encoding of emotionally salient information using an olfactory fear conditioning
procedure. Evidence from our laboratory has shown that activation of CB1 receptors in
discrete mesocorticolimbic regions can significantly potentiate the salience of an
emotional memory, while blockade of CB1 receptor transmission blocks emotional
associative learning in this paradigm (Lauzon et al., 2009; Laviolette, 2006; Tan et al.,
2010). However, the effects of distinct, marijuana-specific, compounds on the encoding
of emotionally salient associative memories are not well understood. In the current study,
we performed several pharmacological behavioural experiments in which rats received
microinfusions of CBD or Δ9-THC into the shell subdivision of the nucleus accumbens
(NASh), a structure that is sensitive to cannabinoids (Mahler et al., 2007; Zangen et al.,
2006) and plays a crucial role in emotional processing and motivated behaviour (Di
Chiara, 2002; Di Chiara et al., 2004). We report that Δ9-THC microinfusions potentiated
the acquisition of a subthreshold fear memory through a DA-dependent mechanism. In
contrast, CBD microinfusions were effective at blocking the acquisition of a
suprathreshold fear memory through a 5-HT1A-dependent mechanism. CBD was also
effective at abolishing Δ9-THC-induced potentiation of a subthreshold fear memory.
Implications for neuropsychiatric disorders are discussed.

3.2 Materials and Methods
3.2.1 Animals and Surgery
	
  
Male Sprague Dawley rats (300-350g) were obtained from Charles River Laboratories
(Quebec, CAN). Rats were anesthetized with an intraperitoneal (i.p.) injection of a
ketamine (80mg/ml)-xylazine (6mg/kg) mixture and meloxicam (1.0 mg/kg; s.c.) was
administered preoperatively in order to reduce pain and post-surgical inflammation.
Following an assessment of anesthetic depth, rats were immobilized using a Kopf
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stereotaxic device. Using sterile technique, an incision was made to expose the skull.
Guide cannulae (22-gauge) were implanted bilaterally into the NASh using flat skull
stereotaxic coordinates as follows (12o angle, in mm from bregma): anteroposterior (AP)
+ 1.8, lateral (LAT) ± 2.6, ventral (V) -7.4 from the dural surface. All stereotaxic
coordinates were based upon the atlas of Paxinos and Watson (1996). Cannulae were
secured to the skull using four small jeweler’s screws and dental acrylic. Dust-caps were
used to ensure the patency of the cannulae. All procedures were performed in accordance
with the Canadian Council on Animal Care (CCAC) and were approved by Western
University’s Council on Animal Care.

3.2.2 Post-Surgery SOP
	
  
Rats were injected subcutaneously with 3 – 10 mL of physiological saline in order to
prevent dehydration. Rats recovered in a clean home cage filled with wood shavings and
warmed under a heat lamp. Behaviour was monitored until recovery from the anesthetics
and sternal recumbency attained. A maintenance dose of meloxicam (1.0 mg/kg) was
administered (s.c.) 24 hours post-surgery in order to reduce pain and inflammation.
Following at least one week of recovery, rats were then tested in behaviorual paradigms.

3.2.3 Olfactory fear conditioning
	
  
All rats were conditioned using a fully counterbalanced olfactory fear conditioning
procedure, as described previously (Lauzon et al., 2009; Laviolette, 2005). Rats were
taken from their home cages and received sham microinfusions into the NASh before
being habituated for 30 min to the conditioning apparatus, a ventilated chamber with a
metallic electric grid floor. Conditioning took place 24 hrs later in one of two visually
distinct environments. The first environment was a 30” x 30” Plexiglas box with black
stripes on a white background and a metallic electric grid floor (shock environment A).
The second environment was a 30” x 30” Plexiglas box with black dots on a white
background and a metallic grid floor (shock environment B). Testing occurred 24 hrs
later in one of two alternate environments in which rats did not receive electric foot
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shock. The first environment was a 30” x 30” Plexiglas box with black stripes on a white
background and a grey Plexiglas floor (test environment A), while the second
environment had black dots on a white background with a gray Plexiglas floor (test
environment B). This fear conditioning procedure is context independent as rats are
conditioned and tested in distinct environments, with only olfactory conditioning cues
being consistent across the experimental procedure. On day 1 (habituation), rats were
habituated to a random combination of shock environment A or B and test environment A
or B for 30 min in each environment. On day 2 (conditioning) rats were placed in their
previously assigned shock environment. During conditioning, one of two distinct odours
(almond or peppermint) were presented for 19s, followed by a 1s footshock (CS+) of
either 0.4 mA or 0.8 mA. The alternate odour is presented 120s later for a duration of 20s
in the absence of a footshock (CS-). This procedure is repeated five times. By modulating
the intensity of foot shock administered (either a subthreshold foot shock of 0.4 mA that
normally does not produce an associative fear memory, or a suprathreshold foot shock of
0.8 mA that produces robust fear memory), we can examine how specific
pharmacological manipulations can either potentiate normally non-salient emotional
memory events, or block the encoding of highly salient emotional memory events
(Laviolette, 2006).
Testing occurred 24hrs after conditioning, when rats were placed in their previously
assigned test environment. Rats were permitted to explore the testing apparatus for 1 min
before odour presentation, during which time baseline levels of freezing and exploratory
behaviour were recorded. Rats were then exposed to the CS+ and CS- odours for 5
minutes in a counterbalanced fashion and the percentage of time the rat spent “freezing”,
a measure of conditioned fear, was recorded. Freezing was defined as complete
immobility with the exception of respiratory-related movements.
3.2.4 Drug administration
	
  
The broad-spectrum DA receptor antagonist, α-flupenthixol, the highly specific 5-HT1B
receptor antagonist, GR-55562, the GABAA antagonist, bicuculline methiodide, and the
GABAB antagonist, hydroxysaclofen, were dissolved in physiological saline (pH adjusted
to 7.4). The 5-HT1A receptor antagonist, NAD-299 hydrochloride, and CBD were
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dissolved in dimethyl sulfoxide (DMSO, Fisher Scientific). Δ9-THC was dissolved in
100% ethanol and cremophor EL (Sigma-Aldrich). Ethanol was removed using nitrogen
stream evaporation and the final solution was diluted with filtered saline. For NASh
microinfusions, stainless steel guide cannulae (22-gauge) were implanted bilaterally into
the NASh through a 28-gauge microinfusion injector (Plastics One). Bilateral
microinfusions were performed over 1 min through a Hamilton microsyringe. In order to
ensure the diffusion of the drug away from the injector tip, the internal cannulae were left
in place for an additional minute. All drugs were purchased from Tocris Biosciences.

3.2.5 Histology
	
  
Following completion of experiments, rats were transcardially perfused, brains were
extracted and stored in a specimen vial containing formalin with 25% sucrose solution for
at least 24hrs. The region of the projected cannulae placements were cut into 40 µm
coronal sections, mounted, and stained using cresyl violet to allow for histological
examination of the injection site. The majority of NASh placements were localized within
the region of the shell of the nucleus accumbens. Rats found to have injectors situated
outside the anatomical boundaries of the NASh were excluded from experimental
analysis.
3.2.6 Data analysis
	
  
Data were analyzed with a mixed-model ANOVA with a between subjects factor of
treatment, and a within subjects factor of stimulus, followed by paired-samples t-tests.

3.3 Results	
  
3.3.1 Histological analysis
	
  
Histological analysis revealed microinfusion injector cannulae placements to be
bilaterally localized within the anatomical boundaries of the shell subdivision of the
nucleus accumbens, according to the Rat Brain Atlas (Paxinos & Watson, 1996). Figure
8A presents a microphotograph displaying a typical injector placement within the NASh.
Figure 8B displays a schematic illustration showing representative intra-NASh bilateral
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cannuale placements along the rostral-caudal axis of the nucleus accumbens. Rats with
cannulae placements located outside of the NASh were removed from data analysis.

	
  
Figure 8. Histological analysis of intra-NASh microinjection sites. A,
Microphotograph of a representative injector placement within the shell subdivision (Sh)
of the NAcc. Injectors located in the core (Co) were removed from analyses. B,
Schematic representation of select intra-NASh injector locations; • = 100ng CBD group,
♦ = 100ng Δ9-THC group.
	
  

3.3.2 Intra-NASh Δ9-THC microinfusion potentiates the formation of a
subthreshold fear memory through a DA-dependent mechanism
	
  
In order to test the hypothesis that intra-NASh Δ9-THC would potentiate the formation of
a subthreshold fear memory, rats received microinfusions of intra-NASh Δ9-THC, 50ng
(n = 8) or 100ng (n = 7), prior to olfactory fear conditioning with a subthreshold (0.4mA)
footshock. In follow-up experiments, animals received 100ng Δ9-THC co-administered
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with either 100ng (n = 5) or 1.0µg (n = 5) of the DA receptor antagonist α-flupenthixol,
or 100ng (n = 5) of the 5-HT1A receptor antagonist NAD-299 (Figure 9).
A mixed-model ANOVA revealed that the main effect of treatment was
significant, F (5, 29) = 4.13, p = .006, indicating that the mean percentage of time spent
freezing was significantly different between treatment groups. The main effect of
stimulus was significant, F (1, 29) = 50.07, p = .000, indicating a significant difference in
the mean percentage of time rats spent freezing in response to the CS+ and CS- odours.
Finally, the interaction between stimulus and treatment was significant, F (5, 29) = 8.90,
p = .000, suggesting that the mean percentage of time spent freezing to the CS+ and CSodours significantly differs as a function of treatment group. Follow-up paired samples ttests revealed that rats receiving vehicle microinfusions did not spend a significantly
higher percentage of time freezing to the CS+ odour (M = 10.36, SD = 1.69) than to the
CS- odour (M = 9.83, SD = 1.81), t (5) = -0.386, p = .72. In contrast, intra-NASh Δ9-THC
microinfusions potentiated the acquisition of the subthreshold associative fear memory.
Rats receiving Δ9-THC at doses of 50ng (MCS- = 12.88, SDCS- = 4.06; MCS+ = 30.07,
SDCS+ = 4.54), t

(7)

= -6.631, p = .000, and 100ng (MCS- = 19.85, SDCS- = 3.32; MCS+ =

39.48, SDCS+ = 5.19), t (6) = -3.493, p = .013, spent significantly more time freezing to the
CS+ odour as compared to the CS- odour. The effect of Δ9-THC was abolished when
rats were co-administered with the DA receptor antagonist α-flupenthixol. Rats receiving
concurrent α-flupenthixol at doses of 100ng (MCS- = 20.86, SDCS- = 5.64; MCS+ = 22.74,
SDCS+ = 6.59), t (4) = -.797, p = .47, and 1.0µg (MCS- = 12.7973, SDCS- = 2.04076; MCS+ =
12.4313, SDCS+ = 1.69558), t

(4)

= .371, p = .73, did not spend significantly more time

freezing to the CS+ odour as compared to the CS- odour. The effect of Δ9-THC was not
blocked by the 5-HT1A receptor antagonist NAD-299. Rats co-infused with 100ng NAD299 spent significantly more time freezing to the CS+ odour (M = 40.75, SD = 5.76) as
compared to the CS- odour (M = 15.03, SD = 4.31), t (3) = -4.822, p = .017.
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Figure 9. Mean (±SEM) percentage of time spent freezing to the CS+ and CS- for
rats microinfused with intra-NASh Δ9-THC. Intra-NASh Δ9-THC potentiates the
formation of an associative fear memory to a normally non-salient, subthreshold (0.4mA)
foot shock. Co-administration of the DA receptor antagonist α-flupenthixol blocks Δ9THC-induced fear memory potentiation. In contrast, co-administration of the 5-HT1A
receptor antagonist NAD-299 does not does not block Δ9-THC-induced fear memory
potentiation. * p < .05.
	
  
3.3.3 Intra-NASh CBD microinfusion blocks the formation of a suprathreshold fear
memory through a 5-HT1A-dependent mechanism
	
  
In order to test the hypothesis that intra-NASh CBD would block the formation of a
suprathreshold fear memory, rats received microinfusions of intra-NASh CBD, 10ng (n =
8) or 100ng (n = 8), prior to olfactory fear conditioning with a suprathreshold (0.8mA)
footshock. In follow-up experiments, animals received 100ng CBD co-administered with
either 10ng (n = 7) or 100ng (n = 7) of the 5-HT1A receptor antagonist NAD-299, 100ng
(n = 7) of the 5-HT1B receptor antagonist GR-55562, or 100ng (n = 4) of the DA receptor
antagonist α-flupenthixol (Figure 10).
A mixed-model ANOVA revealed that the main effect of treatment was not
significant, F (6, 41) = 1.61, p = .169, indicating that the mean percentage of time spent
freezing was not significantly different between treatment groups. The main effect of
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stimulus was significant, F (1, 41) = 39.76, p = .000, indicating a significant difference in
the mean percentage of time rats spent freezing in response to the CS+ and CS- odours.
Finally, the interaction between stimulus and treatment was significant, F (6, 41) = 4.25,
p = .002, suggesting that the mean percentage of time spent freezing to the CS+ and CSodours significantly differs as a function of treatment group. Follow-up paired samples ttests revealed that rats receiving vehicle microinfusions spent a significantly higher
percentage of time freezing to the CS+ odour (M = 59.95, SD = 27.06) than to the CSodour (M = 41.50, SD = 25.77), t

(6)

= -2.49, p = .047. In contrast, intra-NASh CBD

microinfusions blocked the acquisition of the suprathreshold associative fear memory.
Rats receiving CBD at doses of 10ng (MCS- = 16.55, SDCS- = 6.46; MCS+ = 22.60, SDCS+ =
13.31), t

(7)

= -2.11, p = .073, and 100ng (MCS- = 30.81, SDCS- = 24.37; MCS+ = 43.61,

SDCS+ = 27.10), t

(7)

= -2.18, p = .065, did not spend significantly more time freezing to

the CS+ odour as compared to the CS- odour. The effect of CBD was abolished when
rats were co-administered with the 5-HT1A receptor antagonist NAD-299. Rats receiving
concurrent NAD-299 at doses of 10ng (MCS- = 23.43, SDCS- = 15.75; MCS+ = 56.98, SDCS+
= 35.15), t

(6)

= -3.81, p = .009, and 100ng (MCS- = 29.52, SDCS- = 10.17; MCS+ = 60.43,

SDCS+ = 21.48), t

(6)

= -4.65, p = .004, spent significantly more time freezing to the CS+

odour as compared to the CS- odour. The effect of CBD was not blocked by the 5-HT1B
receptor antagonist GR-55562. Rats co-infused with 100ng GR-55562 did not spend
significantly more time freezing to the CS+ odour (M = 44.13, SD = 32.61) as compared
to the CS- odour (M = 38.47, SD = 30.79), t (6) = -1.63, p = .154. Additionally, the effect
of CBD was not blocked by the DA receptor antagonist α-flupenthixol. Rats co-infused
with 100ng α-flupenthixol did not spend significantly more time freezing to the CS+
odour (M = 27.44, SD = 12.07) as compared to the CS- odour (M = 29.36, SD = 18.07), t
(3)

	
  

= 0.335, p = .759.
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Figure 10. Mean (±SEM) percentage of time spent freezing to the CS+ and CS- for
rats microinfused with intra-NASh CBD. Intra-NASh CBD prevents the formation of
an associative fear memory to a normally highly salient, suprathreshold (0.8mA) foot
shock. Co-administration of the 5-HT1A receptor antagonist NAD-299 rescues the
acquisition of suprathreshold fear memory. In contrast, co-administration of the 5-HT1B
receptor antagonist GR-55562 or the DA receptor antagonist α-flupenthixol does not does
not rescue the acquisition of this fear memory. * p < .05
	
  
3.3.4 Intra-NASh CBD microinfusion blocks Δ9-THC-induced potentiation of a
subthreshold fear memory
	
  
Based on emerging evidence, which suggests that CBD antagonizes many of the
behavioural and pharmacological effects of Δ9-THC, we performed a separate
experiment in which rats received intra-NASh microinfusions of 100ng CBD in
combination with 100ng Δ9-THC prior to fear conditioning with a subthreshold
footshock in order to examine whether CBD was able to block Δ9-THC-induced
potentiation of a subthreshold fear memory (Figure 11). A paired samples t-test revealed
that 100ng CBD was able to block the potentiation effect of 100ng Δ9-THC, t (7) = -0.67,
p = .53. Rats did not spend significantly more time freezing to the CS+ odour (M =
32.59, SD = 26.03) as compared to the CS- odour (M = 29.83, SD = 28.23). These data
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are in line with a wealth of evidence that supports a modulatory role of CBD over the
psychotomimetic effects of Δ9-THC.
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Figure 11. Mean (±SEM) percentage of time spent freezing to the CS+ and CS- for
rats microinfused with intra-NASh CBD and Δ9-THC. Intra-NASh 100ng Δ9-THC
potentiates the formation of an associative emotional memory to a normally non- salient,
subthreshold (0.4mA) foot shock. This effect is abolished by co- administration with
100ng CBD, which blocks Δ9-THC-induced potentiation of a subthreshold fear memory.

3.4 Discussion
	
  
Dysfunctions in accurately processing the emotional significance of incoming sensory
stimuli and coordinating normative cognition and appropriate behavioural responses are
pervasive deficits in individuals suffering from schizophrenia (Kohler & Martin, 2006).
This is suggestive of dysfunctions in the mesocorticolimbic system, the underlying
neurocircuitry that regulates emotional information processing (Grace, 2000). Indeed,
imaging studies of schizophrenia patients reveal severe structural and functional
abnormalities in various mesocorticolimbic structures (Ellison-Wright & Bullmore,
2009). Furthermore, evidence suggests a positive correlation between the severity of
psychotic symptoms and the degree of impairment in emotional processing (CrespoFacorro et al., 2001). The nucleus accumbens (NAcc) plays a central role in emotional
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processing as it sends and receives projections to a number of other mesocorticolimbic
structures (Heimer, Zahm, Churchill, Kalivas, & Wohltmann, 1991), integrates
information from these regions and produces goal-directed behavioural outputs (Goto &
Grace, 2008). In particular, the shell subdivision of the nucleus accumbens (NASh) is a
structure that has been implicated in the etiology of schizophrenia, and has been
suggested as a novel and efficacious target for antipsychotic medications (Deutch, Lee, &
Iadarola, 1992).
Although the precise mechanisms underlying cannabis-induce psychosis remain
unknown, evidence is mounting to suggest alterations in cortical and limbic emotional
processing regions as key factors. Previous studies have found that Δ9-THC induces
elevations in DAergic tone in the VTA (French et al., 1997) and the NAcc (Gardner et al.,
1988; Oleson & Cheer, 2012) and can induce transient psychotic symptoms following
even acute exposure (Bhattacharyya et al., 2012). Furthermore, dysfunctions in cortical
endocannabinoid signaling have been implicated in the abberant emotional experiences in
patients with paranoid schizophrenia (Dalton et al., 2011), and structural alternations
have been observed in the NAcc and amygdala in regular cannabis users (Gilman et al.,
2014). Taken together, these data suggest that cannabinoid action at structures involved
in emotional processing may represent a potential mechanism that contributes to the
emotional disturbances observed in cannabis-induced, schizophrenia-related psychosis.
Our previous work has shown that modulation of CB1 transmission in the BLA—
mPFC pathway can mediate the emotional valence of an associative fear memory in an
olfactory fear-conditioning paradigm. Activation of CB1 receptors in these areas results
in the potentiation of normally non-salient emotional associative memories, while CB1
receptor blockade prevents the formation of conditioned fear memories (Laviolette &
Grace, 2006; Tan et al., 2011). We report here that CBD and Δ9-THC can similarly
modulate emotional memory formation in the NASh, and provide further insight into how
cannabis-specific cannabinoids may elicit disturbances in emotional information
processing.
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3.4.1 Intra-NASh Δ9-THC potentiates the formation of a subthreshold fear memory
through a DA-dependent mechanism
	
  
Given our previous findings that activation of CB1 receptors can potentiate non-salient
emotional experiences in discrete mesocorticolimbic structures, we performed a series of
behavioural experiments in which rats received microinfusions of Δ9-THC into the NASh
prior to fear conditioning with a subthreshold (0.4mA) footshock. Our analyses revealed
that while rats treated with vehicle microinfusions did not form a significant fear memory
to the odour paired with a non-salient subthreshold footshock, those treated with Δ9-THC
(50, 100ng) demonstrated a potentiation of associative fear memory formation as
measured by a significant increase in the percentage of time spent freezing in response to
the shock-paired odour (CS+). Based on evidence showing that Δ9-THC administration
increases mesolimbic DA levels (Oleson & Cheer, 2012), we performed follow-up
experiments in which we challenged our highest behaviourally effective dose of Δ9-THC
(100ng) with co-administration of α-flupenthixol (100ng, 1.0µg), a DA receptor
antagonist. Our results revealed that antagonism of DA receptors in the NASh was
sufficient to block Δ9-THC-induced potentiation of a subthreshold footshock. A final
follow-up experiment in which Δ9-THC was challenged with NAD-299, a 5-HT1A
antagonist, revealed that 5-HT1A signaling was not necessary for Δ9-THC-induced
potentiation of a subthreshold footshock (Figure 9).
These data suggest that the disturbances in emotional processing induced by Δ9THC are in part dependent on DA signaling substrates in the NASh, and may provide a
mechanism to explain the propsychotic effects of Δ9-THC and other potent cannabinoids.
Abnormalities in endocannabinoid and DAergic signaling have been implicated in the
aberrant emotional processing observed in schizophrenia (Dalton et al., 2011; Hall et al.,
2004; Moore, West, & Grace, 1999), and previous research has shown that the
endocannabinoid and DAergic systems functionally interact such that cortical CB1
transmission modulates subcortical mesolimbic DA activity (Bossong & Niesink, 2010;
Diana et al., 1998). Indeed, cannabis use is known to induce alterations in sensory
perception: environmental stimuli may become more salient and their emotional valence
may be amplified (Green et al., 2003; Wachtel et al., 2002). These effects share many
similarities with the cognitive, social and emotional disturbances observed in
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schizophrenia, and CB1 receptor activation has been shown to exacerbate psychotic and
cognitive symptoms in schizophrenia patients (Bossong, Jansma, Bhattacharyya, &
Ramsey, 2014; D’Souza et al., 2005).
In the current study, the aberrant emotional processing induced by acute Δ9-THC
administration was abolished with concurrent administration of α-flupenthixol, a DA
receptor antagonist and potent antipsychotic. Previous research implicates disruptions in
DAergic signaling in the NAcc as an etiological factor in schizophrenia (Goto & Grace,
2008; Grace, 2000). Taken together, this suggests that intra-NASh Δ9-THC may have
induced alterations in accumbal DAergic tone that manifests at the behavioural level as
distortions in emotional information processing (Pezze & Feldon, 2004). Indeed, Δ9THC, like all known drugs of abuse, induces DA release from the VTA to the NAcc
(Bossong et al., 2008; French et al., 1997; Gardner, 2005; Tanda & Goldberg, 2003),
presumably by inhibiting GABAergic interneuron activity in the VTA (Szabo, Siemes, &
Wallmichrath, 2002).
The NAcc modulates mesolimbic DA levels by sending direct and indirect
GABAergic projections to the ventral tegmental area (VTA) via medium spiny neurons
(MSN; Xia et al., 2011). The VTA in turn sends DAergic projections back to the NAcc
and other mesocorticolimbic structures ( Ferreira et al., 2008; Grace et al., 2007; Heimer
et al., 1991). CB1 receptors are highly expressed on presynaptic GABAergic interneurons
in limbic structures (Elphick & Egertova, 2001; Pertwee & Ross, 2002; Rodriguez,
Mackie, & Pickel, 2001). Thus it is possible that Δ9-THC’s activation of CB1 receptors
located on presyanptic GABAergic interneurons in the NASh disinhibits MSN projection
neurons to the VTA. This in turn would inhibit VTA GABAergic interneurons, hence
releasing VTA DAergic projection neurons from tonic inhibition and, thus, exciting DA
release from the VTA to the NAcc (see Figure 12). This model, in combination with our
behavioural results, is in line with evidence suggesting that increased DA release from
the VTA to the NASh potentiates behavioural responding to conditioned aversive stimuli
(Pezze & Feldon, 2004), and provides a potential mechanism to explain the propsychotic
properties of Δ9-THC.
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Figure 12. Proposed model for the pharmacological action of Δ9-THC in the NAccVTA pathway. DA: dopamine; MSN: medium spiny neuron; NAcc: nucleus
accumbens; VTA: ventral tegmental area.
	
  
3.4.2 Intra-NASh CBD blocks the formation of a suprathreshold fear memory
through a 5-HT1A-dependent mechanism
	
  
Given CBD’s antagonistic action at CB1 receptors, we performed behavioural
experiments in which rats received intra-NASh microinfusions of CBD (10, 100ng) prior
to conditioning with a suprathreshold footshock in order to examine whether CBD was
effective at blocking the acquisition of an associative fear memory similar to what was
observed with synthetic CB1 receptor antagonists in previous studies (Laviolette &
Grace, 2006; Tan et al., 2011). Our results indicate that CBD was effective at blocking
the acquisition of a highly salient suprathreshold fear memory. This effect was dependent
on 5-HT1A receptor signaling, however was independent of 5-HT1B and DA receptor
signaling (Figure 10).
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Numerous studies have shown CBD to be effective at attenuating the acquisition
and expression (Gomes et al., 2012; Lemos, Resstel, & Guimarães, 2010), and facilitating
the extinction (Bitencourt, Pamplona, & Takahashi, 2008), of conditioned fear. Although
the current results indicate that CBD’s effects in the NASh depend on 5-HT1A receptor
signaling; it is not possible to rule out alternative pharmacological mechanisms. Recent
studies reveal CBD to have a wide range of pharmacological actions, which may explain
its profound effect in fear conditioning paradigms including: antagonism of CB1
receptors (Thomas et al., 2009), agonistic action at 5-HT1A receptors (Russo et al., 2005),
and inhibition of FAAH, the enzyme which catalyzes the degradation of AEA one of the
major endocannabinoids and endogenous ligands of the CB1 receptor (Bisogno et al.,
2001).
Interestingly, CB1 receptor transmission, 5-HT1A receptor signaling and AEA
tone have all been implicated as playing critical roles in the acquisition, expression and
extinction of conditioned fear responses. For example, CB1 receptor antagonism has been
shown to block the acquisition of a highly salient associative fear memory (Laviolette,
2006; Tan et al., 2011), and mice lacking the CB1 receptor show impairments in
extinction learning in associative fear paradigms (Cannich et al., 2004; Marsicano et al.,
2002). Agonists of the 5-HT1A receptor facilitate fear extinction in animals conditioned to
aversive stimuli (Saito et al., 2012), and mice lacking the 5-HT1A receptor show increased
fear responses to contextual fear cues (Klemenhagen, Gordon, David, Hen, & Gross,
2005). Furthermore, a study by Gomes et al. (2012) demonstrated that microinfusions of
CBD into the bed nucleus of the stria terminalis attenuates behavioural expression in a
fear conditioning paradigm and that this effect is blocked with 5-HT1A receptor
antagonism. Other studies found that inhibition of AEA reuptake was effective at
facilitating the extinction of conditioned fear (Bitencourt et al., 2008; Chhatwal, Davis,
Maguschak, & Ressler, 2004). Our results are thus in line with a growing body of
research demonstrating the diverse pharmacological and behavioural effects of CBD in an
associative fear conditioning paradigm. These findings are particularly notable, however,
as we have extended these findings to a discrete neuroanatomical structure, specifically
the shell subdivision of the NAcc.
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From a mechanistic perspective, it is possible that CBD exerts its
neuropsychological effects in precisely the opposite manner of Δ9-THC. While Δ9-THC
presumably activates intra-NASh CB1 receptors on presynaptic GABAergic interneurons,
ultimately resulting in increased VTA DAergic output to the NASh, CBD likely blocks
intra-NASh presynaptic CB1 receptors on GABAergic interneurons, allowing

MSN

GABAergic projection neurons to be inhibited. This frees intra-VTA GABAergic
interneurons from tonic inhibition allowing them in turn to inhibit DAergic projection
neurons back to the NASh and thus decreasing DAergic tone in the NASh (Figure 13).
This theoretical model is in line with the results from our electrophysiology studies
discussed earlier (see section 2.4.4).
CBD’s modulation of the formation and recall of emotionally salient associative
memories has interesting implications for its use as an effective pharmacotherapy in
various neuropsychiatric disorders such as addiction and post-traumatic stress disorder
(PTSD). These disorders are characterized by recurrent, persistent and intrusive recall of
memories associated with emotionally salient experiences, which infringes upon normal
cognition. These may be aversive traumatic experiences as in PTSD, or drug-related
reward memories in the case of addiction, in which the individual is unable to suppress
the spontaneous recall of memories associated with those experiences (Rothbaum &
Davis, 2003). Indeed, recent studies have shown CBD to be effective at attenuating
PTSD-like symptoms and facilitate extinction of aversive associative memories in fear
conditioning paradigms, which model many features of the disorder (Bitencourt et al.,
2008; Campos et al., 2012; Lemos et al., 2010; Resstel, Joca, Moreira, Corrêa, &
Guimarães, 2006). Furthermore, individuals suffering from PTSD have been shown to
have reductions in circulating endocannabinoid levels (Hill et al., 2013) and that
treatment with CBD helps to alleviate many symptoms of PTSD (Greer, Grob, &
Halberstadt, 2014; Passie, Emrich, Karst, Brandt, & Halpern, 2012). This effect is
presumably due to CBD’s ability to raise endocannabinoid tone by inhibiting the
degradation of AEA.

CBD administration has also been found to be effective at

attenuating opioid-seeking behaviour in rats trained to self-administer heroin, and even
normalized mesolimbic neuronal disturbances induced by chronic heroin administration
(Ren, Whittard, Higuera-Matas, Morris, & Hurd, 2009). Emerging basic and clinical
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evidence suggests that CBD and other cannabinoids represent potentially effective
therapeutic compounds in the treatment of PTSD (Greer et al., 2014; Neumeister, 2012;
Passie et al., 2012) and various other neuropsychiatric disorders such as schizophrenia,
anxiety and depression (Mechoulam et al., 2007; Schubart et al., 2013; Scuderi et al.,
2009; Zuardi et al., 2006).

	
  
Figure 13. Proposed model for the pharmacological action of CBD in the NAcc-VTA
pathway. DA: dopamine; MSN: medium spiny neuron; NAcc: nucleus accumbens;
VTA: ventral tegmental area.
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3.4.3 Intra-NASh CBD blocks Δ9-THC-induced potentiation of a subthreshold fear
memory
	
  
Numerous lines of basic and clinical evidence show a dissociation between CBD and Δ9THC at both the pharmacological and behavioural levels (Bhattacharyya et al., 2009b;
Fusar-Poli et al., 2009; Pertwee, 2008; Petitet et al., 1998; Vann et al., 2008). These
effects may be attributable to Δ9-THC and CBD’s differential pharmacological action at
CB1 receptors. Given the opposing pharmacological and behaviorual properties of Δ9THC and CBD, and the substantial evidence which suggests that CBD attenuates many of
the psychopharmacological actions of Δ9-THC, we completed a separate study in which
rats received microinfusion of intra-NASh Δ9-THC (100ng) in combination with CBD
(100ng) prior to being conditioned with a subthreshold foot shock, in order to determine
if CBD was effective at blocking Δ9-THC-induced potentiation of fear memory. The
infusion doses were chosen based on our maximally effective doses from each of the Δ9THC and CBD experiments.
Our results (Figure. 11) reveal that co-administration of CBD is sufficient to block
fear memory potentiation induced by Δ9-THC administration. These results are in line
with recent evidence demonstrating that CBD is effective at antagonizing many of the
psychopharmacological effects of Δ9-THC. In humans, pre-treatment with CBD has been
shown to be effective in attenuating the appetitive (Morgan, Freeman, Schafer, & Curran,
2010), propsychotic (Bhattacharyya, Fusar-Poli, et al., 2009a) and anxiogenic (Englund
et al., 2012; Zuardi, Shirakawa, Finkelfarb, & Karniol, 1982) effects induced by Δ9-THC
administration. In animals, there is evidence that CBD can modulate the heterogenous
reinforcing properties of Δ9-THC by attenuating both its aversive and rewarding effects
(Vann et al., 2008).
Given the results from our electrophysiology experiments with CBD
microinfusions, its seems likely that CBD antagonized the excitation of VTA DAergic
neurons induced by Δ9-THC microinfusion (French et al., 1997), and therefore abolished
its potentiation of a non-salient subthreshold stimulus.
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3.5 Summary	
  

	
  
This study presents evidence for the dissociable and opposite effects of Δ9-THC and
CBD on emotional memory acquisition. Our results support the diverse pharmacological
properties of plant cannabinoids as well as their pharmacokinetic interactions, which have
been established by recent research efforts, and findings presented from complimentary
studies from our laboratory (see Chapter 2). Future studies should examine the
electrophysiological changes induced by intra-NASh Δ9-THC and CBD in emotional
regulation structures (e.g., VTA, amygdala) during olfactory fear conditioning in
anesthetized rats (as described in Laviolette, 2005), in order to more fully elucidate the
neurophsyiological mechanisms that underlie cannabinoid-mediated effects on emotional
information processing.
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Chapter 4. General Conclusions and Future Directions
The work presented in this thesis represents one of the first systematic evaluations of
phytocannabinoid effects in discrete neural substrates during emotional learning
paradigms and describes novel pharmacological mechanisms for their action.
Specifically, the results from our CPP experiments are the first demonstration that CBD
possess hedonic rewarding properties in the NASh, an effect that was dependent on 5HT1A, 5-HT1B and DAergic signaling. Furthermore, intra-NASh CBD administration
elicited a depression in VTA DA neural activity, a novel electrophysiological effect that
suggests a potential alternative mechanism for CBD’s well-known antipsychotic
properties, as well as its ability to oppose the effects of Δ9-THC.
The results from our olfactory fear conditioning experiments reveal that Δ9-THC
can potentiate the formation of a subthreshold associative fear memory similar to the
effect observed with synthetic CB1 receptor agonists. This effect was dependent on
DAergic receptor signaling; supporting the observation that Δ9-THC elicits increased
mesolimbic DA transmission. In the same paradigm, CBD was shown to be effective at
blocking the formation of an aversive fear memory to a normally highly salient
suprathreshold footshock in a manner similar to that observed with synthetic CB1
receptor antagonists. This effect was dependent on the 5-HT1A, but not the 5-HT1B,
receptor signaling mechanism. These results suggest a functional dissociation between
the neurophysiological mechanisms underlying aversive and appetitive memory
formation as CBD’s rewarding properties were dependent on 5-HT1B receptor
transmission in the CPP paradigm. These results also support emerging basic and clinical
research suggesting the possible use of CBD as an efficacious pharmacotherapy in a
number of psychiatric disorders such as schizophrenia, PTSD and addiction.
The results of these studies suggest many possible avenues for future
investigation. Future studies should continue our electrophysiology experiments in order
to characterize the neuroelectrophysiological nature underlying the switch in CBD’s
motivational valence following 5-HT1A receptor antagonism. Extensions of our olfactory
fear conditioning experiments should examine electrophysiological changes that may
occur following intra-NASh Δ9-THC and CBD administration in other areas of the
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mesocorticolimbic system including the BLA and the mPFC. Finally, although not
presented in this thesis, preliminary work investigating Δ9-THC reward in the CPP
paradigm has revealed a strong correlation between the location of Δ9-THC
microinfusions along the rostral-caudal axis of the NASh and appetitive-aversive
behavioural reactions to Δ9-THC administration. Follow-up studies should employ
targeted microinfusions into the rostral and caudal NASh in order to further elucidate the
nature of this hedonic gradient.
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